People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Weight loss drugs, already a relatively new and revolutionary concept within the medical industry, are shaking things up once again. Move over Ozempic, pharmaceutical giant Eli Lilly […] ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

We recently published a list of the 13 Best American Dividend Stocks to Buy According to Analysts. In this article, we are ...

Doctors and patients have been hoping for a pill version that would be easier to take, in contrast to an injectable.

President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless ...

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...